{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:31:32Z","timestamp":1793183492914,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1124\/jpet.115.223784","type":"journal-article","created":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T22:33:24Z","timestamp":1436481204000},"page":"394-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis"],"prefix":"10.1016","volume":"354","author":[{"given":"Tomoki","family":"Fukuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"B\u00e4umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.115.223784_bib1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/ACI.0000000000000093","article-title":"What\u2019s new in the topical treatment of allergic skin diseases","volume":"14","author":"Aslam","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1124\/jpet.115.223784_bib2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1476-5381.2012.01836.x","article-title":"Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study","volume":"166","author":"Balagu\u00e9","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.115.223784_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tox.2005.09.013","article-title":"TDI can induce respiratory allergy with Th2-dominated response in mice","volume":"218","author":"Ban","year":"2006","journal-title":"Toxicology"},{"key":"10.1124\/jpet.115.223784_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1365-2133.2004.06220.x","article-title":"TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis. Effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines","volume":"151","author":"B\u00e4umer","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1124\/jpet.115.223784_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejphar.2003.09.031","article-title":"Effects of cilomilast on dendritic cell function in contact sensitivity and dendritic cell migration through skin","volume":"481","author":"B\u00e4umer","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.115.223784_bib6","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1124\/jpet.115.223784_bib7","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/jid.2009.25","article-title":"Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis","volume":"129","author":"Boy","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.115.223784_bib8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1124\/jpet.115.223784_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2003-07-2412","article-title":"Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression","volume":"103","author":"Chen","year":"2004","journal-title":"Blood"},{"key":"10.1124\/jpet.115.223784_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jvp.12087","article-title":"The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog","volume":"37","author":"Collard","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1124\/jpet.115.223784_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/vde.12047","article-title":"Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis","volume":"24","author":"Cosgrove","year":"2013","journal-title":"Vet Dermatol"},{"key":"10.1124\/jpet.115.223784_bib12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/vde.12088","article-title":"A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel\u00ae) in client-owned dogs with atopic dermatitis","volume":"24","author":"Cosgrove","year":"2013","journal-title":"Vet Dermatol"},{"key":"10.1124\/jpet.115.223784_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.113.209304","article-title":"Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis","volume":"348","author":"Dowty","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.115.223784_bib14","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":"Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation","volume":"131","author":"Fridman","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.115.223784_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000347184","article-title":"Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis","volume":"91","author":"Fujii","year":"2013","journal-title":"Pharmacology"},{"key":"10.1124\/jpet.115.223784_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL\u00ae) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1124\/jpet.115.223784_bib17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"10.1124\/jpet.115.223784_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-3083.2006.01877.x","article-title":"Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis","volume":"21","author":"Hijnen","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1124\/jpet.115.223784_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.0022-202X.2004.22324.x","article-title":"Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells","volume":"122","author":"Hoetzenecker","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.115.223784_bib20","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.4049\/jimmunol.160.11.5331","article-title":"Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses","volume":"160","author":"Homey","year":"1998","journal-title":"J Immunol"},{"key":"10.1124\/jpet.115.223784_bib21","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar4673","article-title":"Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials","volume":"16","author":"Isaacs","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1124\/jpet.115.223784_bib22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1081-1206(10)62611-7","article-title":"Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate","volume":"82","author":"Kimata","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1124\/jpet.115.223784_bib23","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.115.223784_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1600-6143.2003.00281.x","article-title":"The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models","volume":"4","author":"Kudlacz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1124\/jpet.115.223784_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","article-title":"An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow","volume":"223","author":"Lutz","year":"1999","journal-title":"J Immunol Methods"},{"key":"10.1124\/jpet.115.223784_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond)"},{"key":"10.1124\/jpet.115.223784_bib27","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.4049\/jimmunol.1100649","article-title":"Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC\/Nga mice via suppression of Th2 and enhancement of Th17","volume":"187","author":"Nakagawa","year":"2011","journal-title":"J Immunol"},{"key":"10.1124\/jpet.115.223784_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrd1441","article-title":"A new modality for immunosuppression: targeting the JAK\/STAT pathway","volume":"3","author":"O\u2019Shea","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.115.223784_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1067\/mai.2001.112600","article-title":"Human epidermal Langerhans\u2019 cells are targets for the immunosuppressive macrolide tacrolimus (FK506)","volume":"107","author":"Panhans-Gross","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1124\/jpet.115.223784_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1124\/jpet.115.223784_bib31","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.4049\/jimmunol.168.9.4361","article-title":"Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin","volume":"168","author":"Ratzinger","year":"2002","journal-title":"J Immunol"},{"key":"10.1124\/jpet.115.223784_bib32","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/jid.2008.454","article-title":"Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration","volume":"129","author":"Reines","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.115.223784_bib33","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) Part II","volume":"26","author":"Ring","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1124\/jpet.115.223784_bib34","doi-asserted-by":"crossref","first-page":"e7066","DOI":"10.1371\/journal.pone.0007066","article-title":"Jak3 is involved in dendritic cell maturation and CCR7-dependent migration","volume":"4","author":"Rivas-Caicedo","year":"2009","journal-title":"PLoS One"},{"key":"10.1124\/jpet.115.223784_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0625.2008.00762.x","article-title":"Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation","volume":"18","author":"Rossbach","year":"2009","journal-title":"Exp Dermatol"},{"key":"10.1124\/jpet.115.223784_bib36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.223784_bib37","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nm1643","article-title":"Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system","volume":"13","author":"Steinman","year":"2007","journal-title":"Nat Med"},{"key":"10.1124\/jpet.115.223784_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","article-title":"Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo","volume":"64","author":"Tanimoto","year":"2015","journal-title":"Inflamm Res"},{"key":"10.1124\/jpet.115.223784_bib39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-2008-1034313","article-title":"Evaluation of antipruritic effects of red ginseng and its ingredients in mice","volume":"74","author":"Trinh","year":"2008","journal-title":"Planta Med"},{"key":"10.1124\/jpet.115.223784_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J Immunol"},{"key":"10.1124\/jpet.115.223784_bib41","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","article-title":"Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1124\/jpet.115.223784_bib42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1124\/jpet.115.223784_bib43","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/jpet.115.223784_bib44","first-page":"A2089","article-title":"The role of the JAK\/STAT pathway in a lipopolysaccharide-induced mouse model of acute lung injury","volume":"185","author":"Yew-Booth","year":"2012","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524191082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524191082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.115.223784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:35:28Z","timestamp":1739975728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524191082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0022356524191082"],"URL":"https:\/\/doi.org\/10.1124\/jpet.115.223784","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.115.223784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}